Vision-Sciences Reports Financial Results of Second Quarter

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Vision-Sciences Reports Financial Results of Second Quarter and First Half Fiscal 2015

ORANGEBURG, N.Y., Nov. 5, 2014 (GLOBE NEWSWIRE) -- Vision-Sciences, Inc. (Nasdaq: VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath ® technology, today announced financial results for the second quarter and first six months of fiscal (FY) 2015, ended September 30, 2014. Highlights include:

  • Second quarter of FY 2015 net sales of $4.1 million, a 4% increase as compared with $4.0 million in second quarter of FY 2014. Sequentially, net sales in the second quarter increased by 9% from the first quarter of FY 2015. For the first half of FY 2015, net sales increased by 3% to $7.9 million as compared with $7.6 million in the first half of FY 2014;
  • Medical sales of $3.3 million and $6.3 million for the second quarter and first half of FY 2015, respectively, a decrease of 4% and 2% respectively, over the corresponding prior-year periods. Excluding sales to Stryker Corporation, medical sales of $2.9 million and $5.5 million for the second quarter and first half of FY 2015, respectively, an increase of 32% and 36%, respectively, over the corresponding prior-year periods; in May 2014 the Company decided not to renew an agreement with Stryker for the sale of Vision-Sciences' cystoscopy products.
  • International sales of medical products were $1.4 million and $2.9 million for the second quarter and first half of FY 2015, respectively, an increase of 37% and 33%, respectively, over the corresponding prior-year periods;
  • Net loss of $(1.5) million in the second quarter of FY 2015 as compared with $(1.3) million in the prior-year quarter. Net loss improved by 6% to $(3.5) million for the first half of FY 2015 as compared with $(3.8) million in the prior-year period. Net loss per basic and diluted common share was unchanged at $(0.03) and $(0.08) for the second quarters and first halves, respectively, of FY 2015 and FY 2014;
  • Net cash used in operating activities was $1.8 million for the first half of FY 2015, a significant improvement from $3.2 million in the prior-year period; and,
  • Successfully launched two new products in September 2014: the BRS-5100 Video Bronchoscope in Europe and the world's smallest video laryngoscope, the ENT-7000, in the U.S.

"Since implementing our strategic initiatives almost a year ago, our driving goal has been to deliver profitable growth. We are focused on building sales of higher-margin products to support our goal. The significant growth realized by all of our businesses, excluding sales to Stryker, has shown that this strategy is beginning to have a positive impact. In addition, for the last three quarters, we have continued to reduce our operating and net loss while simultaneously reducing net cash used in operating activities," commented Howard Zauberman, President and Chief Executive Officer of Vision-Sciences, Inc.

"Following our strategic decision in May to regain the sales of our cystoscopy line from Stryker, we have worked diligently to transform this formerly dilutive product line to one of profitability. To date, we have converted approximately 90% of the active Stryker customer base to Vision-Sciences' customers. We believe that by focusing on the office based small and large group urology practices and ambulatory surgery centers, where most cystoscopies are performed, we will achieve our goal.

"Going forward, we will continue to expand and round out our product line, and broaden our sales focus, with the goal of becoming cash-flow neutral to positive in the foreseeable future," concluded Mr. Zauberman.

Results of Operations

Net sales in the second quarter of fiscal (FY) 2015 increased by 4% to $4.1 million as compared with $4.0 million in the same period one year ago. Higher sales in our urology and ENT markets were offset in part by lower sales in our TNE and pulmonology markets. Excluding sales to Stryker Corporation, sales in our medical business were $2.9 million, an increase of 32% compared with the same period one year ago.

Net sales in the first half of FY 2015 increased by 3% to $7.9 million compared with $7.6 million in the prior-year period, as higher sales in our urology, ENT and pulmonology markets were offset in part by lower sales in our TNE market.

Industrial sales in the second quarter of FY 2015 increased by 48% to $0.8 million compared with $0.6 million in the same period one year ago. In the first half of FY 2015, industrial sales increased by 29% to $1.5 million as compared with $1.2 million in the first half of FY 2014. Growth in both periods was primarily due to the addition of new customers.

Net sales detail (in thousands, except for percentages) for the second quarter and first half of fiscal years 2015 and 2014 is as follows:

  Three Months Ended   Six Months Ended  
  September 30,   September 30,  
Market/Category 2014 2013 % 2014 2013 %
  (unaudited) (unaudited)   (unaudited) (unaudited)  
Urology $1,928 $1,681 15% $3,701 $3,542 4%
ENT 510 403 27% 761 743 2%
TNE 76 355 -79% 257 558 -54%
Pulmonology 227 395 -43% 592 481 23%
Repairs, peripherals and accessories 526 565 -7% 1,016 1,104 -8%
Total net medical sales $3,267 $3,399 -4% $6,327 $6,428 -2%
Total net industrial sales 843 569 48% 1,535 1,192 29%
Net Sales $4,110 $3,968 4% $7,862 $7,620 3%

Gross profit increased 5% to $1.3 million for the second quarter of FY 2015. Gross profit as a percent of net sales increased to 30.6% for the second quarter of FY 2015 as compared with 30.1% in the prior-year period.  For the first half of FY 2015, gross profit increased 6% to $2.4 million. Gross profit as a percent of net sales increased to 30.6% for the first half of FY 2015 as compared with 29.9% in the prior-year period. The increases in gross profit and gross profit as a percent of net sales are primarily attributable to a shift in sales mix toward higher margin products and to our cost-savings measures driven by our strategy to improve profitability.

Selling, general and administrative ("SG&A") expense was $2.4 million in the second quarter of FY 2015, an increase of $0.3 million, or 15%, compared with the prior-year period.  The second quarter of FY 2014 included the reversal of stock-based compensation expense related to the departure of our former chief executive officer.  In the first half of FY 2015, SG&A expense was $4.8 million, a decrease of $0.3 million, or 5%, compared with the prior-year period. The improvement is primarily attributable to our cost-savings measures, as well as severance expense in the prior-year period.

Research and development ("R&D") expense was $0.3 million for the second quarter of FY 2015, a decrease of $0.1 million, or 20%, compared with the same period last year, primarily attributable to lower product development costs and the timing of expenses. For the first half of FY 2015, R&D expenses increased 4% over the same period last year.

In the second quarter of FY 2015, the Company's operating loss increased by $0.2 million, or 12%, to $(1.4) million as compared with the prior-year period, primarily due to the higher SG&A expense as previously discussed.  In the first half of FY 2015, the operating loss improved by $0.4 million, or 10%, to $(3.3) million as compared with the prior-year period, primarily due to lower SG&A expense and higher gross margin.

The Company reported a net loss of $(1.5) million, or $(0.03) per basic and diluted share, for the second quarter of FY 2015 versus a net loss of $(1.3) million, or $(0.03) per basic and diluted share, for the second quarter of FY 2014. For the first half of FY 2015, the net loss improved to $(3.5) million, or $(0.08) per basic and diluted share, as compared with a net loss of $(3.8) million, or $(0.08) per basic and diluted share, for the prior-year period.

At September 30, 2014, the Company had cash and cash equivalents of $1.4 million and working capital of $5.9 million, compared with cash and cash equivalents of $1.2 million and working capital of $6.9 million at March 31, 2014.  Net cash used in operating activities was $1.8 million for the first half of FY 2015, an improvement from $3.2 million in the same period one year ago. On June 16, 2014, the Company issued a convertible promissory note to Lewis C. Pell, our Chairman, which allows us to borrow up to $5.0 million.  As of the date of this press release, we have $3.0 million in principal outstanding under the note.

Conference Call

Howard Zauberman, President and Chief Executive Officer, and Gary Siegel, Vice President, Finance, will host a conference call to discuss the second quarter fiscal 2015 financial results at 8:30 a.m. EST, on Thursday, November 6, 2014.

Conference dial-in:  (877) 303-1595
International dial-in:  (970) 315-0449
Conference ID:  22049644
Webcast:  http://ir.visionsciences.com/

An audio replay of the conference call will be available from 11:30 a.m. EST on Thursday, November 6, 2014, through 11:59 p.m. EST on Thursday, November 13, 2014, by dialing (855) 859-2056 from the U.S. or (404) 537-3406 from abroad. The audio webcast will also be available in the investor section of the Company's website, www.visionsciences.com .

About Vision-Sciences, Inc.

Vision-Sciences, Inc. designs, develops, manufactures and markets products for flexible endoscopy. The Company's unique product lines feature a streamlined visualization system and proprietary sterile disposable microbial barrier, known as EndoSheath technology, providing users with efficient and cost effective endoscope turnover while enhancing patient safety. Information about Vision-Sciences' products is available at www.visionsciences.com .

Vision-Sciences, Inc. owns the registered trademarks Vision Sciences ® , EndoSheath ® , EndoWipe ® , Slide-On ® , and The Vision System ® .

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements, which are any statements that are not historical facts. These forward-looking statements are based on Vision-Sciences' current expectations, and should not be relied upon as representing its views as of any subsequent date. Forward-looking statements are subject to a variety of risks and uncertainties that could cause the Company's actual results to differ materially from the statements contained herein; risk factors are detailed in the Company's most recent annual report and other filings with the U.S. Securities and Exchange Commission. There is no assurance that any future results or events discussed in these statements will be achieved. The Company does not assume any obligation to update any forward-looking statements as a result of new information or future events or developments, except as may be required by law.

(Financial tables follow)

Vision-Sciences, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations
(in thousands, except per share amounts)
(Unaudited)
         
  Three Months Ended Six Months Ended
  September 30, September 30,
  2014 2013 2014 2013
         
Net sales  $ 4,110  $ 3,968  $ 7,862  $ 7,620
Cost of sales  2,852  2,773  5,455  5,345
Gross profit  1,258  1,195  2,407  2,275
         
Selling, general, and administrative expenses  2,358  2,050  4,849  5,100
Research and development expenses  341  428  877  847
Operating loss  (1,441)  (1,283)  (3,319)  (3,672)
         
Interest expense  (106)  (44)  (189)  (85)
Other, net  4  7  (12)  3
Loss before provision for income taxes  (1,543)  (1,320)  (3,520)  (3,754)
Income tax provision  --   3  --   3
Net loss  $ (1,543)  $ (1,323)  $ (3,520)  $ (3,757)
         
Net loss per common share - basic and diluted  $ (0.03)  $ (0.03)  $ (0.08)  $ (0.08)
         
Weighted average shares used in computing net loss per common share - basic and diluted  46,327  46,144  46,294  46,127
 
Vision-Sciences, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(in thousands)
  September 30, March 31,
  2014 2014
ASSETS (unaudited)  
Current assets:    
Cash and cash equivalents  $ 1,395  $ 1,237
Accounts receivable, net  2,920  3,818
Inventories, net  4,221  4,194
Prepaid expenses and other current assets  460  455
Total current assets  8,996  9,704
     
Property and equipment, net  986  1,062
Other assets, net  67  67
Total assets  $ 10,049  $ 10,833
     
LIABILITIES AND STOCKHOLDERS' DEFICIT    
Current liabilities:    
Accounts payable  $ 1,405  $ 1,217
Accrued expenses  880  918
Accrued compensation  514  474
Deferred revenue  310  210
Capital lease obligations  --   22
Total current liabilities  3,109  2,841
     
Convertible debt—related party  24,480  22,414
Deferred revenue, net of current portion  128  93
Total liabilities  27,717  25,348
     
Commitments and Contingencies    
Stockholders' deficit:    
Preferred stock, $0.01 par value    
Authorized—5,000 shares; issued and outstanding - none  --   -- 
Common stock, $0.01 par value    
Authorized—100,000 shares; issued and outstanding—47,793 shares and 47,614 shares, respectively  478  476
Additional paid-in capital  103,000  102,629
Treasury stock at cost, 65 shares and 59 shares of common stock, respectively  (85)  (78)
Accumulated deficit  (121,061)  (117,542)
Total stockholders' deficit  (17,668)  (14,515)
Total liabilities and stockholders' deficit  $ 10,049  $ 10,833
     
Vision-Sciences, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(in thousands)
(Unaudited)
     
  Six Months Ended
  September 30,
  2014 2013
Cash flows from operating activities:    
Net loss  $ (3,520)  $ (3,757)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization  318  362
Stock-based compensation expense  349  328
Provision for bad debt expenses  11  7
Amortization of debt discount  66  -- 
Loss (gain) on disposal of fixed assets  9  (5)
Changes in assets and liabilities:    
Accounts receivable  887  802
Inventories  (261)  (712)
Prepaid expenses and other current assets  (5)  (117)
Accounts payable  188  (112)
Accrued expenses  (38)  50
Accrued compensation  40  (96)
Deferred revenue  135  22
Net cash used in operating activities  (1,821)  (3,228)
Cash flows from investing activities:    
Purchases of property and equipment  (17)  (46)
Proceeds from disposal of fixed assets  --   3
Net cash used in investing activities  (17)  (43)
Cash flows from financing activities:    
Proceeds from issuance of convertible debt—related party  2,000  3,000
Proceeds from exercise of stock options  25  -- 
Common stock repurchased  (7)  (28)
Payments of capital leases  (22)  (34)
Net cash provided by financing activities  1,996  2,938
Net increase (decrease) in cash and cash equivalents  158  (333)
Cash and cash equivalents at beginning of period  $ 1,237  $ 788
Cash and cash equivalents at end of period  $ 1,395  $ 455

Gary Siegel Vice President, Finance Vision-Sciences, Inc. (845) 365-0600 Lisa Wilson President In-Site Communications, Inc. (212) 452-2793

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Katahdin's Portland Branch Bet Moves Downtown in 2027

Updated Category News Views 61

Exchange Street is getting a real-world vote of confidence, and that is more interesting than another app update ever will be. Katahdin Trust intends to open a full-service branch at 120 Exchange Street in downtown Portland, with renovations slated to begin early in 2027 and an opening expected later that year. For a Maine community bank with nearly $1.2 billion in...

Continue Reading
Washington-to-Asia Advisory Deal Targets Policy Risk

Updated Category News Views 10

Policy bottlenecks are becoming a cost center across Southeast Asia. That is the plain-English backdrop for the strategic partnership announced November 18, 2026, by Beacon Global Strategies and Vriens & Partners. Neither firm is selling a factory, a chip design, or a new energy project. They are selling something companies increasingly cannot afford to improvise: a...

Continue Reading
APEC's Shared-Prosperity Message Needs More Detail

Updated Category News Views 20

Geese make handsome symbols, but markets cannot underwrite a metaphor. The Nov. 18, 2026 report from Xinhua News Agency looks back to remarks Chinese President Xi Jinping made 12 years ago, when he used swan geese to urge APEC economies toward greater cooperation and a new collective flight. Its present-day message is plainly hopeful: the APEC family is moving across the...

Continue Reading
CVRx Lawsuit Deadline Follows a Brutal 59.76% Plunge

Updated Category News Views 24

A 59.76% one-day wipeout has a way of stripping the varnish off every upbeat corporate story. For CVRx investors, the hard fact is that the shares fell $3.55 to close at $2.39 on August 7, 2026, after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. That kind of disclosure does not merely dent confidence; it forces...

Continue Reading
Haemonetics Opens Europe for VASCADE MVP XL Device

Updated Category News Views 31

A larger collagen plug is hardly cocktail-party material, yet it can matter a great deal when it sits inside a procedure workflow hospitals are trying to speed up. Haemonetics has received CE Mark certification under the EU Medical Device Regulation for VASCADE MVP XL, its larger-bore venous vascular closure system, and first commercial European procedures were completed...

Continue Reading
Fapon’s Enzyme Push Meets Diagnostics Reality at AMP

Updated Category News Views 85

Enzymes rarely get applause at industry meetings, but they can quietly decide whether a diagnostic workflow behaves or becomes a lab headache. Fapon used its AMP 2026 appearance in Seattle to make that unglamorous case: better enzyme design may help assays move faster and keep working when samples get messy. The company wrapped up the November 10–14 meeting after...

Continue Reading
Photocure Opens a New Access Route for Hexvix Patients

Updated Category News Views 31

Forty-plus markets just moved from “not available” toward a workable route for individual bladder cancer patients, and that is the real substance of Photocure’s new arrangement with Clinigen. This is not a sweeping product launch, nor is it an approval announcement dressed up in confetti. It is a Named Patient Program, which matters because the regulatory plumbing...

Continue Reading
Kids First Data Sharing Raises Pediatric Research Bar

Updated Category News Views 68

Thirty-eight thousand children’s records are not a headline gimmick; they are a serious argument for treating research data as an asset that must keep working after the first study ends. The Gabriella Miller Kids First Data Resource Center’s ten-year review, published in the September 2026 issue of The American Journal of Human Genetics, makes that argument with...

Continue Reading
DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 68

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
WYBOT's New Robots Push Hands-Free Pool Care in Lyon

Updated Category News Views 0

A pool robot climbing out of the water to dock itself is the sort of demo that makes people stop mid-aisle at a trade show. WYBOT brought precisely that kind of attention-grabber to Piscine Global Lyon 2026, running November 17–20 at Eurexpo Lyon. The company is showing a broader lineup, but the M3 Pro is plainly the headline act: WYBOT calls it the world's first...

Continue Reading

Top 5 Most Recently Viewed Articles

Michael Baker International Enhances Pavement Management Strategies

Updated Category News Views 313

Michael Baker International Teams Up with CVAG Michael Baker International, a well-known leader in engineering and consulting services, has recently been selected by the Coachella Valley Association of Governments (CVAG) for an important project focused on improving the area's pavement condition assessments. This partnership marks a significant step toward enhancing the...

Continue Reading
Fidus Investment Corporation Announces $100 Million Note Offering

Updated Category News Views 307

Fidus Investment Corporation's Recent Offering Announcement Fidus Investment Corporation (NASDAQ: FDUS) has recently made a significant announcement regarding its financial strategy. The company has priced an underwritten public offering of 6.750% notes, with an aggregate principal amount of $100 million, due in 2030. This initiative is aimed at strengthening its capital...

Continue Reading
WillScot Strengthens Board with New Appointment to Drive Growth

Updated Category News Views 49

WillScot Appoints Worthing Jackman to Board of Directors WillScot Holdings Corporation (NASDAQ: WSC), a leader in flexible space and storage solutions, has made a strategic move by appointing Worthing Jackman to its Board of Directors. This significant addition is aimed at reinforcing the company's growth strategy and bolstering its financial and operational performance....

Continue Reading
National Press Club Reacts to Pentagon's New Media Restrictions

Updated Category News Views 510

Concerns Regarding Pentagon's Media Access Restrictions Recently, the National Press Club leadership voiced significant concerns about new media restrictions imposed by the Pentagon. A statement from the club highlighted that these restrictions threaten transparency and reduce public access to information critical for accountability. Impact on Journalistic Integrity...

Continue Reading
Dogecoin and Shiba Inu Surge: A New Era for Meme Coins

Updated Category News Views 100

A Look at the Recent Surge in Dogecoin and Shiba Inu Recently, Dogecoin and Shiba Inu, both leaders in the meme coin market, have experienced notable price spikes. Dogecoin's value has risen by 4.5%, while Shiba Inu has jumped an impressive 8%. These increases follow important economic news about a cut in interest rates, which is bringing renewed optimism among crypto...

Continue Reading